Wet Age-Related Macular Degeneration
A Phase I Open-label, Multiple-cohort, Dose-escalation Study to Evaluate the Safety and Tolerability of Gene Therapy With RGX-314 in Subjects With Neovascular Age-Related Macular Degeneration
A Phase III Randomized, Double-masked, Parallel Group, Multicenter Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity Between SB11 and Lucentis® in Subjects With Neovascular Age-related Macular Degeneration
A Phase II, Multi-Center, Randomized, Double Masked and Active Controlled Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in combination with Lucentis® Compared to Lucentis® Monotherapy in Subjects with Wet AMD
A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Neovascular Age-Related Macular Degeneration
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study To Evaluate The Efficacy And Safety Of Faricimab In Patients With Neovascular Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration
A Phase II/III Randomized, Double Masked, Controlled Trial to Assess the Safety and Efficacy of Intravitreous Administration of Zimura® (Anti-C5 Aptamer) in Subjects with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Diabetic Macular Edema
A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator Controlled Study To Evaluate The Efficacy And Safety Of RO6867461 In Patients With [both previously treated and treatment naïve] DME
A Prospective, Randomized, Double-Masked, Active Comparator-controlled, Multi-center, Two-arm, Phase III Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME)
A Randomized, Double-Masked, Active-Controlled Phase 2/3 study of the Efficacy and Safety of High-Dose Aflibercept in patients with Diabetic Macular Edema
A Phase III, Three-Arm, Randomized, Double-Masked, Multicenter Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to DME
Diabetic Retinopathy
A Phase II Randomized, Open Label Study to Evaluate Safety of Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement
Peripheral Diabetic Retinopathy (DR)Lesions on Ultrawide-field Fundus Images and Risk of DR Worsening Over Time
Treatment for Central-Involved Diabetic Macular Edema in Eyes With Very Good Visual Acuity
Intravitreous Anti-Vascular Endothelial Growth Factor Treatment for Prevention of Vision Threatening Diabetic Retinopathy in Eyes at High Risk
Retinal Vein Occlusion
A Phase I/Ib Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics Following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects With Wet Age-Related Macular Degeneration (wAMD), Diabetic Macular Edema (DME) and Retinal Vein Occlusion (RVO)
A Phase II, Multicenter, Open-label, Safety and Proof-of-concept Study to Assess Safety, Tolerability and Efficacy of AR-1105 in Subjects With Macular Edema Due to Retinal Vein Occlusion (RVO)
Nevus/Melanoma
Phase 1b Open-Label, single ascending dose clinical trial designed to evaluate the safety of two dose levels of light-activated AU-011-101 for the treatment of subject with small to medium (2.0mm-3.4mm thickness) primary choroidal melanoma
Identification of Germline BAP1 Mutation In Subjects With Choroidal Nevi or Uveal Melanoma
Radiation Retinopathy
The ARRT trial will assess the safety and efficacy of 2mg IAI for the treatment of radiation retinopathy, including maculopathy and optic neuropathy
Non-proliferative Diabetic Retinopathy
A Phase IIa Randomized, Double-masked, Placebo-controlled Exploratory Study to Evaluate Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Orally Administered BI 1467335 for 12 Weeks with a 12-Week Follow Up Period in Patients with Non-Proliferative Diabetic Retinopathy without center-involved Diabetic Macular Edema
